Indivior UK Limited
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as RB Pharmaceuticals Limited (to 2015)
7
Ending by 2030
Feb 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 1 to 13, 2027 · next Feb 1
- 1 fee due Mar 12, 2027The maintenance fee for Therapeutic Compounds (US 11,753,398) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 3 fees due Jun 12 to 30, 2027 · next Jun 12
- 1 fee due Jul 2, 2027The maintenance fee for Syringe System (US 11,857,498) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Injectable Flowable Composition Comprising Buprenorphine (US 10,558,394) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 5 fees due Sep 1 to 29, 2027 · next Sep 1
- 1 fee due Oct 7, 2027The maintenance fee for Therapeutic Compounds as Inhibitors of the OREXIN-1 Receptor (US 10,611,760) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Methods to Treat Opioid Use Disorder (US 10,646,484) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 5 terms have ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,376,590 | Sustained delivery formulations of risperidone compound In force · From the USPTO record | In force | From the USPTO record | |
| US 11,013,809 | Sustained delivery formulations of risperidone compound In force · From the USPTO record | In force | From the USPTO record | |
| US 11,712,475 | Sustained delivery formulations of risperidone compound In force · From the USPTO record | In force | From the USPTO record | |
| US 8,207,355 | Method for Preparing Azetidine Derivatives In force · High confidence | In force | High confidence | |
| US 9,687,454 | Sublingual and Buccal Film Compositions In force · Medium confidence | In force | Medium confidence | |
| US 11,135,216 | Sublingual and Buccal Film Compositions In force · Medium confidence | In force | Medium confidence | |
| US 8,475,832 | Sublingual and Buccal Film Compositions In force · High confidence | In force | High confidence | |
| US 9,272,044 | Injectable Flowable Composition Buprenorphine In force · High confidence | In force | High confidence | |
| US 9,498,432 | Injectable Flowable Composition Comprising Buprenorphine In force · High confidence | In force | High confidence | |
| US 9,782,402 | Injectable Composition Comprising Buprenorphine In force · High confidence | In force | High confidence |
Also on record, not counted in the 49: 4 patents in force now held by others · 15 lapsed for an unpaid fee · 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 1 abandoned · 12 no status recorded